Company intelligence / Profile preview

Sration

Ownership: Private
Development stage: Other

Overview

Stramsen Biotech has a robust pipeline of 33 drug candidates, with 11 currently in early-stage clinical trials. Some treatments are already available internationally. The company leverages a proprietary medicinal plant database to develop safer, more effective therapies for infectious and noninfectious diseases

Therapeutic areas: OncologyEndocrinologyDermatologyRheumatologyNeurologyCardiovascularNephrologyInfectious Diseases
Modalities: Small moleculePlant-derived compoundBiologic
Industry: Biotech

Partnerships

Lead investor GEM Global Yield LLC SCS

Beyond the preview

Go deeper on Sration.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sration.

Explore the full profile